233 related articles for article (PubMed ID: 31691354)
1. Changes in the commercial brand of tacrolimus lead to subtherapeutic trough levels and acute rejection in renal transplant recipients.
Arreola-Guerra JM; Alberú J; Chew-Wong A; Macias DM; Hernández-Rosales J; Zuñiga-Macías L; Delgadillo-Castañeda R; Ricalde-Ríos G; Haro-Alcalde F; Villafán-Bernal JR; Ramos-Medellín CL; Reyes-Acevedo R
Clin Transplant; 2019 Dec; 33(12):e13749. PubMed ID: 31691354
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.
Seibert SR; Schladt DP; Wu B; Guan W; Dorr C; Remmel RP; Matas AJ; Mannon RB; Israni AK; Oetting WS; Jacobson PA
Clin Transplant; 2018 Dec; 32(12):e13424. PubMed ID: 30318646
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients.
Arreola-Guerra JM; Serrano M; Morales-Buenrostro LE; Vilatobá M; Alberú J
Ann Transplant; 2016 Feb; 21():105-14. PubMed ID: 26879833
[TBL] [Abstract][Full Text] [Related]
4. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation.
Davis S; Gralla J; Klem P; Tong S; Wedermyer G; Freed B; Wiseman A; Cooper JE
Am J Transplant; 2018 Apr; 18(4):907-915. PubMed ID: 28925597
[TBL] [Abstract][Full Text] [Related]
5. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.
Oetting WS; Schladt DP; Guan W; Miller MB; Remmel RP; Dorr C; Sanghavi K; Mannon RB; Herrera B; Matas AJ; Salomon DR; Kwok PY; Keating BJ; Israni AK; Jacobson PA;
Am J Transplant; 2016 Feb; 16(2):574-82. PubMed ID: 26485092
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus trough levels higher than 6 ng/mL might not be required after a year in stable kidney transplant recipients.
Jung HY; Seo MY; Jeon Y; Huh KH; Park JB; Jung CW; Lee S; Han SY; Ro H; Yang J; Ahn C; Choi JY; Cho JH; Park SH; Kim YL; Kim CD
PLoS One; 2020; 15(7):e0235418. PubMed ID: 32614859
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics.
Israni AK; Riad SM; Leduc R; Oetting WS; Guan W; Schladt D; Matas AJ; Jacobson PA;
Transpl Int; 2013 Oct; 26(10):982-9. PubMed ID: 23879408
[TBL] [Abstract][Full Text] [Related]
8. Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients.
Naicker D; Reed PW; Ronaldson J; Kara T; Wong W; Prestidge C
Pediatr Nephrol; 2017 Nov; 32(11):2125-2131. PubMed ID: 28660366
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of tacrolimus intra-patient variability on kidney transplant outcomes according to pre-transplant immunological risk.
Kim EJ; Kim SJ; Huh KH; Kim BS; Kim MS; Kim SI; Kim YS; Lee J
Sci Rep; 2021 Jun; 11(1):12114. PubMed ID: 34108576
[TBL] [Abstract][Full Text] [Related]
10. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
[TBL] [Abstract][Full Text] [Related]
11. The Epidemiologic Burden of Tacrolimus Variability among Kidney Transplant Recipients in the United States.
Shah PB; Ennis JL; Cunningham PN; Josephson MA; McGill RL
Am J Nephrol; 2019; 50(5):370-374. PubMed ID: 31553982
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
13. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
[TBL] [Abstract][Full Text] [Related]
14. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.
Gatault P; Kamar N; Büchler M; Colosio C; Bertrand D; Durrbach A; Albano L; Rivalan J; Le Meur Y; Essig M; Bouvier N; Legendre C; Moulin B; Heng AE; Weestel PF; Sayegh J; Charpentier B; Rostaing L; Thervet E; Lebranchu Y
Am J Transplant; 2017 May; 17(5):1370-1379. PubMed ID: 27862923
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.
Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L
Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809
[TBL] [Abstract][Full Text] [Related]
16. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
Kim SH; Lee SD; Kim YK; Park SJ
Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus exposure in the real world: an analysis from the Mycophenolic acid Observational REnal transplant study.
Shihab FS; Olyaei A; Wiland A; McCague K; Norman DJ
Clin Transplant; 2014 Jul; 28(7):768-75. PubMed ID: 24754603
[TBL] [Abstract][Full Text] [Related]
18. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
Shihab F; Qazi Y; Mulgaonkar S; McCague K; Patel D; Peddi VR; Shaffer D
Am J Transplant; 2017 Sep; 17(9):2363-2371. PubMed ID: 28141897
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients.
Taber DJ; Chokkalingam A; Su Z; Self S; Miller D; Srinivas T
Clin Transplant; 2019 Oct; 33(10):e13679. PubMed ID: 31365151
[TBL] [Abstract][Full Text] [Related]
20. A randomized, open-label pharmacokinetic trial of tacrolimus extended-release dosing in obese de novo kidney transplant recipients.
Jasiak-Panek NM; Wenzler E; Patel S; Thielke JJ; Progar K; Patel S; Brandt S; Huang YJ; Benedetti E; West-Thielke PM
Clin Transplant; 2019 Aug; 33(8):e13640. PubMed ID: 31206808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
